^
Association details:
| Biomarker: | PRCC-TFE3 fusion |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | Xtandi (enzalutamide capsule) (Androgen receptor inhibitor) + 6RK73 (UCHL1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Both SUMOylation and ubiquitination of TFE3 fusion protein regulated by androgen receptor are the potential target in the therapy of Xp11.2 translocation renal cell carcinoma
Excerpt:
...the combination of the AR inhibitor MDV3100 and the UCHL1 inhibitor 6RK73 was effective in delaying the progression of Xp11.2 tRCC, especially PRCC-TFE3 tRCC.
DOI:
10.1002/ctm2.797
